Center-Authored Papers

Filters: Author is Bensinger, William I  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2008
Zaucha R, Gooley TA, Holmberg L, Gopal AK, Press OW, Maloney DG, Bensinger WI.  2008.  High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.. Leukemia & lymphoma. 49(10):1899-906. Abstract
Till BG, Gooley TA, Crawford N, Gopal AK, Maloney DG, Petersdorf SH, Pagel JM, Holmberg L, Bensinger WI, Press OW.  2008.  Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma.. Leukemia & lymphoma. 49(6):1062-73. Abstract
Bensinger WI, Schubert MM, Ang K-K, Brizel D, Brown E, Eilers JG, Elting L, Mittal BB, Schattner MA, Spielberger R et al..  2008.  NCCN Task Force Report. prevention and management of mucositis in cancer care.. Journal of the National Comprehensive Cancer Network : JNCCN. 6 Suppl 1:S1-21;quizS22-4. Abstract
Bensinger WI.  2008.  Stem-cell transplantation for multiple myeloma in the era of novel drugs.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(3):480-92. Abstract
Gopal AK, Metcalfe TL, Gooley TA, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg L, Maloney DG, Press OW.  2008.  High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.. Cancer. 113(6):1344-50. Abstract
2009
Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger WI, Badros AZ, Vescio R et al..  2009.  Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.. Blood. 114(4):772-8. Abstract
Stiff PJ, Bensinger WI, Abidi MH, Gingrich R, Artz AS, Nademanee A, Hansen KS, Sobczak C, Cutler C, Bolwell B et al..  2009.  Clinical and ultrasonic evaluation of spleen size during peripheral blood progenitor cell mobilization by filgrastim: results of an open-label trial in normal donors.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(7):827-34. Abstract
Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T, Agura ED, McSweeney PA, Pulsipher MA, Hari P et al..  2009.  Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.. Blood. 113(14):3383-91. Abstract
Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger WI, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R et al..  2009.  International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 23(10):1904-12. Abstract
Anderson KC, Alsina M, Bensinger WI, Biermann SJ, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA et al..  2009.  NCCN clinical practice guidelines in oncology: multiple myeloma.. Journal of the National Comprehensive Cancer Network : JNCCN. 7(9):908-42.
Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger WI, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R et al..  2009.  Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.. Blood. 114(9):1729-35. Abstract
Bensinger WI.  2009.  Role of autologous and allogeneic stem cell transplantation in myeloma.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 23(3):442-8. Abstract
2010
Bensinger WI, Jagannath S, Vescio R, Camacho E, Wolf J, Irwin D, Capo G, McKinley M, Potts P, Vesole DH et al..  2010.  Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.. British journal of haematology. 148(4):562-8. Abstract
Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K, Dehner C, Gibney C, Bridger G, Calandra G.  2010.  Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.. Bone marrow transplantation. 45(1):39-47. Abstract
2011
Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, Fry J, Afar DEH, Singhal AK.  2011.  A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.. Blood. 120(3):552-559. Abstract
Budde LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg L, Shustov AR et al..  2011.  Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(22):3023-9. Abstract
Anderson KC, Alsina M, Bensinger WI, Biermann SJ, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C et al..  2011.  Multiple myeloma.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(10):1146-83.
Cavo M, Rajkumar VS, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M et al..  2011.  International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.. Blood. 117(23):6063-73. Abstract
2012
Guerrero A, Riddell SR, Storek J, Stevens-Ayers T, Storer BE, Zaia JA, Forman S, Negrin RS, Chauncey TR, Bensinger WI et al..  2012.  Cytomegalovirus Viral Load and Virus-Specific Immune Reconstitution after Peripheral Blood Stem Cell versus Bone Marrow Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(1):66-75. Abstract
Jakubowiak AJ, Benson DM, Bensinger WI, Siegel DSD, Zimmerman TM, Mohrbacher A, Richardson PG, Afar DEH, Singhal AK, Anderson KC.  2012.  Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(16):1965. Abstract
Bensinger WI, Rotta M, Storer B, Chauncey T, Holmberg L, Becker P, Sandmaier BM, Storb R, Maloney D.  2012.  Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center.. Bone marrow transplantation. 47(10):1312-7. Abstract
Bensinger WI.  2012.  Allogeneic transplantation: peripheral blood vs. bone marrow.. Current opinion in oncology. 24(2):191-196. Abstract
Mielcarek M, Storer B, Martin PJ, Forman SJ, Negrin RS, Flowers ME, Inamoto Y, Chauncey TR, Storb R, Appelbaum FR et al..  2012.  Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow.. Blood. 119(11):2675-2678. Abstract
Gopal AK, Karami M, Mayor J, Macebeo M, Linenberger M, Bensinger WI, Holmberg L.  2012.  The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells.. Journal of clinical apheresis. 27(2):81-7. Abstract
2013
Cassaday RD, Guthrie KA, Budde EL, Thompson L, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Palanca-Wessels MC et al..  2013.  Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(9):1403-6. Abstract